Prevention of metastasis by inhibition of the urokinase receptor.
about
Increased focal adhesion kinase- and urokinase-type plasminogen activator receptor-associated cell signaling in endothelial cells exposed to asbestosRecycling of the urokinase receptor upon internalization of the uPA:serpin complexesProstate stem cell antigen: a cell surface marker overexpressed in prostate cancerThe urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodelingThe role of PTEN in prostate cancer cell tropism to the bone micro-environment.Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on vitronectin.Random peptide bacteriophage display as a probe for urokinase receptor ligands.Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction.Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene.The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis.Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.Pathological significance of vascular endothelial growth factor A isoform expression in human cancer.Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid miceMechanisms of tumour invasion and metastasis: emerging targets for therapy.Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas.Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cellsImaging active urokinase plasminogen activator in prostate cancer.Urokinase type plasminogen activator receptor expression in colorectal neoplasms.High-affinity urokinase receptor antagonists identified with bacteriophage peptide display.Up-regulation of urokinase and urokinase receptor genes in malignant astrocytomaEndotoxin stimulates expression of the murine urokinase receptor gene in vivoAnti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agentThe alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain.alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptorReceptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancerHumoral innate immune response and disease.Is there a genetic signature for liver metastasis in colorectal cancer?Role of urokinase receptor in tumor progression and development.Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes.Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.Urokinase plasminogen activator system as a potential target for cancer therapy.The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis.Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene.Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.
P2860
Q23923072-1491C011-AAEE-4803-86B2-972FF432A068Q24532196-A6DCCBB9-F88C-4CAD-AF09-BCA6993BCA89Q24673693-50116B57-6F1C-465B-81BD-E082BB06F531Q28257803-2AB2726D-468D-4754-9432-AA4F5C56D5A5Q30443138-C3A64764-2879-4DD7-A51A-E536239B41E4Q30470527-08282330-361E-448D-B99A-8ABF2E3C8DDDQ31047145-54334071-B853-4541-AFE6-D33D9582EF75Q31506532-80CFB75C-7FD9-440A-91D8-916EF821B59AQ33865182-BCA1DC4A-BB24-4391-8B53-E751A951FE2AQ34165118-C0DA6435-0518-4A69-8CEB-E534A790D729Q34489359-A1212447-12B6-47D3-8E43-61C53CBB0B38Q34587758-5FE29B15-A9D3-4E96-8071-B158DBDF2238Q34722935-C0FF78DB-2BB3-4CA6-AE4A-121C3D10C5B3Q34774748-06BD84AB-BE1B-45EA-BE74-156DA986937EQ34832169-88DE884C-27BD-4715-80DE-0640E1DAD09CQ34837655-7621E045-6715-453A-B2C7-D00E5774371BQ35004950-B0138C3B-DEAD-4D31-B31C-DFEB8C6C8282Q35147059-6E8077E0-7605-4C21-9BB7-33195C39C6EBQ35220266-1281BC5A-2701-48EE-8A34-73FF17D60D41Q35251858-1FEE55E5-C693-472D-A353-6598BE060DE3Q35353534-F94FB38D-CB1B-4B38-93A2-2269E81632B2Q35617966-DDCAE869-0558-4736-9158-A60CD939C5C1Q35795105-4249B55E-5A89-437A-A6C3-5295CA45B0E8Q35798348-0F012E92-5704-4581-BDA1-E0A05D0CC5D7Q36081353-EC0CF0F6-CCC5-42C0-931C-87DBD84D7A39Q36234767-999E489C-EF1E-45F4-8DB7-F3D84EC220EAQ36236343-B14580B0-E92F-4CAC-8CE3-1D7B1FC52CF4Q36254926-8B25BB8F-13D8-4F61-A59E-60BE0D3BCD24Q36421968-5EDDA8C5-F66B-45D9-AF4A-A25445315DC8Q36623129-4D48A5C6-8F78-4C2A-B3EE-0CB8F95675D3Q36996320-E49EE799-9681-404C-99BF-584012CCA353Q36997616-F403B396-3AEA-4DF0-8CEE-B05A96F2D7EBQ37359182-D3EE5DBF-891B-4755-BDE5-B579F54A33A3Q37369504-23D86E45-A10F-409F-8128-0523A25EE178Q37561638-3E411928-BAEC-4375-9D4D-A927A13A7BF7Q37630593-0A996FE7-B9AB-40A5-AEA1-282665B26416Q37635689-CD241AF2-F156-41A4-B947-92C5E5E9AE7CQ38317155-62BE8D72-C60B-49D0-9583-0C90E18BFC64Q38352946-59232B5D-A96D-432E-8462-30FBC311CCB9Q38601915-5B5E00F8-DC12-4BFD-BE8A-5A864D29F7B2
P2860
Prevention of metastasis by inhibition of the urokinase receptor.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Prevention of metastasis by inhibition of the urokinase receptor.
@ast
Prevention of metastasis by inhibition of the urokinase receptor.
@en
type
label
Prevention of metastasis by inhibition of the urokinase receptor.
@ast
Prevention of metastasis by inhibition of the urokinase receptor.
@en
prefLabel
Prevention of metastasis by inhibition of the urokinase receptor.
@ast
Prevention of metastasis by inhibition of the urokinase receptor.
@en
P2093
P2860
P356
P1476
Prevention of metastasis by inhibition of the urokinase receptor.
@en
P2093
P2860
P304
P356
10.1073/PNAS.90.11.5021
P407
P577
1993-06-01T00:00:00Z